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Mycobacterium avium complex (MAC) causes serious opportunistic infections in AIDS patients. Previous
studies with MAC-infected beige mice have indicated that weekly administration of liposome-encapsulated
streptomycin can reduce significantly the CFU in the liver and spleen. We examined whether streptomycin
encapsulated in recently developed sterically stabilized liposomes with prolonged circulation times would have
a therapeutic effect in this animal model. Two liposome types with prolonged circulation (polyethyleneglycoldistearoylphosphatidylethanolamine [PEG-DSPE]–distearoylphosphatidylcholine [DSPC]–cholesterol [chol]
or phosphatidylinositol [PI]-DSPC-chol) and conventional liposomes (phosphatidylglycerol [PG]-phosphatidylcholine [PC]-chol) encapsulating streptomycin and administered twice weekly were bactericidal to MAC
strain 101 in the spleen when the level of infection after treatment was compared with the level of infection
before treatment. PI-DSPC-chol and PG-PC-chol liposomes encapsulating streptomycin were bactericidal in
the liver. Although PG-PC-chol or PEG-DSPE–DSPE–chol liposomes encapsulating streptomycin were not
bactericidal in the lungs, they reduced the level of MAC infection by more than 3 orders of magnitude
compared with the level of MAC infection in untreated controls.
have not been investigated previously. In the study described
here we examined the effect on MAC infection in beige mice of
streptomycin encapsulated in liposomes of two different compositions that are known to have prolonged circulation times
and compared the effect with the effect of antibiotic encapsulated in conventional liposomes.

Mycobacterium avium complex (MAC) causes serious disease, particularly in human immunodeficiency virus-infected
individuals. The prognosis for MAC-infected AIDS patients is
bleak, and most patients survive less than 1 year after diagnosis
(26). MAC invades resident macrophages in the lungs, liver,
spleen, lymph nodes, and intestines and is also found in blood
during certain phases of the disease (19, 27, 30, 49, 50). To
effectively combat this infection, it is essential to target antibiotics to macrophages in these tissues as well as to attain bactericidal levels in the bloodstream. We have demonstrated
previously that liposome-encapsulated amikacin and streptomycin encapsulated in liposomes are more effective than the
free antibiotics against MAC inside murine or human macrophages (5, 24, 32, 36). In the beige mouse model, intravenous
administration of liposome-encapsulated aminoglycosides was
effective against MAC infections in the liver and spleen even at
weekly doses that were 1/10 to 1/5 of the daily dose of the free
drug (17, 18). The superior efficacy of liposome-encapsulated
antibiotics against MAC has also been demonstrated by other
laboratories (11, 13, 33, 43).
Recently developed liposomes with prolonged circulation
times in the bloodstream have been shown to extravasate into
tissues and localize in tissue macrophages and have been used
for cancer chemotherapy (2–4, 20, 29, 38, 39, 44, 47). Sterically
stabilized liposomes with prolonged circulation times also appear to localize preferentially in Klebsiella-infected lung tissue
rather than in normal tissue (8). To our knowledge, the antimicrobial effects of antibiotics encapsulated in such liposomes
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MATERIALS AND METHODS
Drugs and reagents. Streptomycin was obtained from Pfizer (New York,
N.Y.), and N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid (HEPES) was
purchased from Sigma Chemical Co. (St. Louis, Mo.). Egg yolk phosphatidylcholine (PC), phosphatidylglycerol (PG) prepared from PC, distearoylphosphatidylcholine (DSPC), and plant phosphatidylinositol (PI) were obtained from
Avanti Polar Lipids (Alabaster, Ala.). Polyethylene glycol (PEG)-distearoylphosphatidylethanolamine (DSPE), synthesized with PEG with a molecular mass of
1,900 Da, was a gift from D. Papahadjopoulos (University of California, San
Francisco). Cholesterol (chol) was purchased from Calbiochem (La Jolla, Calif.).
NaCl and KCl were from Fisher (Pittsburgh, Pa.).
Organisms and infection of the animals. A predominantly transparent colony
type of MAC (strain 101; serotype 1), maintained by repeated passages through
beige mice to retain its virulence, was injected into 5- to 7-week-old male beige
(C57B1/6/bgj/bgj) mice via the tail vein (approximately 7 3 106 viable units per
animal). The animals were kept five to a cage in a biohazard room, with food and
water being given ad libitum.
Liposome preparation. Streptomycin was encapsulated in liposomes composed of the following lipid mixtures: (i) PEG-DSPE–DSPC–chol (molar ratio,
1:9:6.7), (ii) PI-DSPC-chol (molar ratio, 1:9:6.7), and (iii) PG-PC-chol (molar
ratio, 1:9:6.7). Lipids (200 mmol of phospholipid or 334 mmol of total lipid) were
dried from a chloroform solution onto the sides of a round-bottom glass flask.
The dried film was then hydrated by the addition of 3.5 ml of a sterile streptomycin solution (168 mg/ml in 10 mM HEPES [pH 7.4], adjusted to an osmolality
of 300 mosM with water by using a Wescor [Logan, Utah] vapor pressure
osmometer). In the case of negative-control liposomes, 100 mmol of phospholipid (or 167 mmol of total lipid) was dried and hydrated with 3.5 ml of HEPES
buffer (10 mM HEPES, 140 mM NaCl, 10 mM KCl [pH 7.4]). Full hydration was
achieved by vortexing. In the case of sterically stabilized liposomes that contained
DSPC (whose gel-liquid crystalline phase transition temperature is 548C in physiological saline), the flask was alternately placed in a 568C water bath and
vortexed. This was followed by four cycles of freezing (in a dry ice-ethanol bath)
and thawing (in a 218C water bath). The liposome preparations were extruded
four times through dual polycarbonate membranes (a 0.4-mm-pore-diameter
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membrane on top of a 0.1-mm-pore-diameter membrane; Nuclepore, Pleasanton, Calif.) under argon pressure in a high-pressure extrusion apparatus (Lipex
Biomembranes, Vancouver, British Columbia, Canada). In the case of the liposome preparations containing DSPC, the extruder was preheated to 568C by
circulating water through the water jacket around the chamber. Unencapsulated
streptomycin was removed by chromatographing the liposome suspension on
sterile Sephadex G-75 equilibrated with argon-saturated HEPES buffer and
eluting with the same buffer. The liposome suspensions were sterilized by passage through a 0.22-mm-pore-diameter filter in the case of the PG-PC-chol
liposomes and a 0.45-mm-pore-diameter filter (Schleicher & Schuell, Keene,
N.H.) in the case of the sterically stabilized liposomes. The mean diameter of
identically prepared liposomes, estimated by dynamic light scattering with a
Coulter (Hialeah, Fla.) NP-4 instrument, was 172 6 40 nm.
The encapsulation of streptomycin was determined by a fluorescence assay
involving the interaction of ninhydrin with guanidino groups as described previously (17). Phospholipid concentrations were determined by phosphate analysis
(9). The amount of encapsulated streptomycin was in the range of 188 to 298 mg
of drug per mmol of phospholipid for the different preparations. The liposomes
containing PI or PEG-DSPE retained 100% of their contents upon storage for 2
weeks at 48C and were used for all of the injections over the 2-week period of
therapy. Liposomes containing PG leaked 38% of the encapsulated streptomycin
upon storage at 48C for 2 weeks. Therefore, in the case of the PG-containing
liposomes, unencapsulated streptomycin was removed from half of the initial
preparation and was used for the injections during the first week. Unencapsulated antibiotic was removed from the remaining half of the preparation 1 week
later, to be used for the injections during the second week.
Treatment and its evaluation. Therapy was initiated 1 day after the infection
of the animals. The infected animals were treated for 2 weeks by twice-weekly
injections of the liposome-encapsulated antibiotics (at doses of 15 or 30 mg/kg of
body weight for the PG-PC-chol or PI-DSPC-chol liposomes and 15 mg/kg for
the PEG-DSPE–DSPC–chol liposomes) via the tail vein. Control animals received injections of HEPES buffer or buffer-loaded control liposomes. The
amounts of lipid to be used for the latter controls were based on the amounts of
lipid injected for each of the preparations (1.39 mmol for the PEG-DSPE–
DSPC–chol liposomes, 2.01 mmol for the PI-DSPC-chol liposomes at the higher
dose, and 3.19 mmol for the PG-PC-chol liposomes at the higher dose). Controls
involving the intravenous injection of free streptomycin and free streptomycin
plus buffer-loaded liposomes were omitted from this experiment, since they had
been investigated in our earlier studies with large unilamellar PG-PC-chol liposomes (21). An additional positive control was the intramuscular injection of 150
mg of free streptomycin per kg 5 days per week for 4 weeks.
The baseline CFU 1 day following infection was determined in the liver,
spleen, and lungs of three randomly selected mice following homogenization and
plating of appropriate dilutions on 7H11 agar medium. The plates were incubated at 378C, and the CFU was determined after 3 weeks of incubation. The
treated animals were sacrificed at 2 and 4 weeks following infection to determine
the CFU in the same organs. The results are expressed as the mean and standard
deviation of the CFU from three mice per experimental point. The statistical
significance of differences between experimental conditions was ascertained by
Student’s t test by using the Statview program (Brainpower, Inc., Calabasas,
Calif.).
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FIG. 1. CFU of MAC in the livers of mice treated with PG-PC-chol (A),
PI-DSPC-chol (B), or PEG-PE–DSPC–chol (C) liposomes. Open bars, untreated
controls; dotted bars, liposome controls; solid bars, 15 mg of streptomycin per kg
in liposomes; striped bars, 30 mg of streptomycin per kg in liposomes. The error
bars represent the standard deviations of the means obtained from three animals.

RESULTS
In the liver, streptomycin encapsulated in PG-PC-chol (Fig.
1A) or PI-DSPC-chol (Fig. 1B) liposomes was very effective in
reducing the CFU counts. Compared with the initial (1 day)
infection, 15 or 30 mg of streptomycin per kg in either liposome composition reduced the CFU by about 2 log units at the
end of the 4-week experiment, indicating a bactericidal effect
(P # 0.005 comparing CFU at day 1 and 4 weeks for both
liposome types at 15 or 30 mg/kg). Compared with the untreated control at the end of the 4-week period, this corresponded to about a 3.4-log-unit reduction in CFU. Streptomycin encapsulated in PEG-DSPE–DSPC–chol liposomes (at a
dose of 15 mg/kg) caused a 1.3-log-unit reduction in the CFU
compared with the CFU of the initial infection (P # 0.025) and
a 2.7-log-unit reduction in the CFU compared with CFU in the
untreated controls at week 4. The difference between the CFU
obtained with 15 mg of streptomycin per kg in PEG-DSPE–
DSPC–chol and either PG-PC-chol or PI-DSPC-chol liposomes was significant (P # 0.005 and P # 0.01, respectively).
Buffer-loaded control liposomes had no effect on the CFU in
the case of PG-PC-chol liposomes, while liposomes of the two
other compositions containing DSPC caused some reduction
in the CFU compared with the CFU in untreated controls,

particularly at 4 weeks (Fig. 1B and C). Intramuscular injections of free streptomycin (at a dose of 150 mg/kg at 5 days per
week for 4 weeks) as a control caused a reduction in CFU of
3.6 log units at the 4-week time point compared with the CFU
in untreated controls (data not shown). It should be noted that
the total dose of antibiotic administered in the latter case was
25- to 50-fold higher than that given in liposomes.
In the spleen, all three liposome compositions caused a 1.8to 2.4-log-unit reduction in CFU at the 4-week point compared
with the CFU at the initial infection (Fig. 2). The difference
between the CFU on day 1 and that obtained with any of the
three liposome types (15 mg of streptomycin per kg) at 4 weeks
was highly significant (P # 0.0005). At a dose of 15 mg of
streptomycin per kg, the reductions in CFU compared with the
CFU in the untreated controls at 4 weeks were 4.3, 4.0, and 4.5
log units for PG-PC-chol, PI-DSPC-chol, and PEG-DSPE–
DSPC–chol liposomes, respectively. The differences in CFU
between the liposomes of the different formulations were not
significant. Control liposomes in all three cases did not have a
significant effect on the MAC CFU in the spleen. The intramuscular injection of free streptomycin as a control produced
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FIG. 2. CFU of MAC in the spleens of mice treated with PG-PC-chol (A),
PI-DSPC-chol (B), or PEG-PE–DSPC–chol (C) liposomes. Open bars, untreated
controls; dotted bars, liposome controls; solid bars, 15 mg of streptomycin per kg
in liposomes; striped bars, 30 mg of streptomycin per kg in liposomes. The error
bars represent the standard deviations of the means obtained from three animals.

FIG. 3. CFU of MAC in the lungs of mice treated with PG-PC-chol (A),
PI-DSPC-chol (B), or PEG-PE–DSPC–chol (C) liposomes. Open bars, untreated
controls; dotted bars, liposome controls; solid bars, 15 mg of streptomycin per kg
in liposomes; striped bars, 30 mg of streptomycin per kg in liposomes. The error
bars represent the standard deviations of the means obtained from three animals.

a CFU reduction of 4.8 log units at 4 weeks compared with the
CFU in the untreated controls (data not shown).
The results obtained in the lungs were of particular interest
because of the inability of previous treatment regimens with
liposome-encapsulated antibiotics used in our laboratories to
affect the CFU significantly. Twice-weekly administration of
streptomycin for 2 weeks in either PG-PC-chol (30 mg/kg) or
PEG-DSPE–DSPC–chol (15 mg/kg) liposomes effected a 3.9or 3.8-log-unit reduction in CFU, respectively, at the 4-week
time point compared with the CFU in untreated controls (Fig.
3A and C). Compared with the initial level of infection on day
1, these CFU represented about a 0.5-log-unit reduction,
which was statistically significant (P # 0.025 for PG-PC-chol
and P # 0.05 for PEG-DSPE–DSPC–chol liposomes). PIDSPC-chol liposomes, on the other hand, caused only about a
2-log-unit reduction in the CFU compared with the CFU in the
untreated controls at 4 weeks (Fig. 3B). Control liposomes did
not show a significant effect on the CFU except for the enhancement noted at 4 weeks for the buffer-loaded PG-PC-chol
liposomes. The intramuscular injections of free antibiotic as a
positive control resulted in a 4.4-log-unit reduction in CFU
compared with the CFU in untreated controls at 4 weeks.

DISCUSSION
Currently available treatments for MAC infections in humans require chemotherapy with multiple drug combinations,
which may clear bacteremia, but they have not been effective in
treating MAC infections in tissues and in prolonging patient
survival (1, 28, 37). In some studies, although a reduction in the
level of bacteremia and improvements in clinical symptoms
were observed, a large percentage of patients developed adverse reactions (12, 31). While monotherapy with clarithromycin appears to be effective (10, 15, 16), the relatively high MBC
of the drug and the potential development of drug resistance
(25) may eventually limit the efficacy of this agent. Therefore,
the development of novel drugs and treatment modalities is
essential for a complete cure of the disease. Our previous
studies with an animal model have shown that aminoglycoside
antibiotics, particularly amikacin and streptomycin, could be
useful either by themselves or in combination with other drugs
like clofazimine, ethambutol, and rifabutin (22, 23). However,
these treatments require prolonged administration of high
doses of aminoglycosides (50 mg/kg for amikacin and 150
mg/kg for streptomycin) that could be toxic.
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One strategy for reducing the dose and frequency of administration of antibiotics is to target them to infected tissues and
cells. We and others have shown that liposome-encapsulated
aminoglycosides can reduce the levels of MAC in the livers and
spleens of infected animals (11, 13, 17, 18, 33, 43). The onceweekly dosage used in our studies, however, was not effective
in the lungs, despite the localization of the antibiotic in this
tissue. This result was ascribed to the trapping of liposomes in
lung capillaries and their inability to localize in lung macrophages (17). Other studies have used daily, twice-weekly, or
three-times-weekly doses of liposome-encapsulated amikacin
or gentamicin and observed some efficacy in reducing the CFU
counts in the lungs compared with the counts in untreated
controls (13, 35). Therefore, in the present study we administered liposomes twice weekly.
In the current study we explored the use of liposomes of
three different compositions that have been shown to have
different half-lives in the bloodstream when they are prepared
and administered under similar experimental conditions. Liposomes with prolonged circulation times, termed ‘‘stealth’’ liposomes because they avoid immediate recognition and removal
by the mononuclear phagocyte system (the reticuloendothelial
system), are generally composed of saturated phospholipids,
cholesterol, and a glycolipid or synthetic lipid component that
confers stability in serum as well as prolonged circulation
times. Thus, these liposomes have also been designated as
being sterically stabilized or surface modified (45, 46). Sterically stabilized liposomes have been shown to localize in implanted tumors, most likely because of their prolonged circulation times in blood and increased microvascular permeation
(20, 39, 48). Such liposomes also have a propensity to localize
in infected lung tissue (8). The percentage of the intravenous
dose remaining in the blood 24 h after injection is 23.6 6 3.1
for PEG-DSPE–DSPC–chol liposomes, while the percentages
are 0.3 6 1 for PG-PC-chol liposomes, 4.1 6 1.3 for PI-PCchol liposomes, and 12.2 6 3.4 for hydrogenated PI-DSPCchol liposomes (45). Clearly, there are considerable differences
in the circulation times of PG-PC-chol and PEG-DSPE–
DSPC–chol liposomes. Our liposomes had compositions similar to those of the liposomes listed above, but they were not
tested for their circulation times. The PI-containing liposomes
that we used contained nonhydrogenated PI in combination
with DSPC. Thus, the levels of these liposomes in blood at 24
h may be expected to be intermediate between 4.1% (PI-PCchol liposomes) and 12.2% (hydrogenated PI-DSPC-chol liposomes). Despite these potential differences in circulation times
between the different liposome types, the reductions in CFU in
the tissues examined were not drastically different.
The results presented in this report show that liposomes of
all three compositions used to encapsulate streptomycin are
effective in reducing by several orders of magnitude the level of
MAC infection in the liver and spleen. Comparing these results
with those obtained after intramuscular injections of free
streptomycin, it is clear that similar reductions in MAC CFU
can be obtained with 25- to 50-fold lower total doses of liposome-encapsulated antibiotics, in agreement with earlier observations (17, 18, 21). Significantly, twice-weekly administration of streptomycin encapsulated in PG-PC-chol or PI-DSPCchol liposomes was bactericidal to MAC in the liver, while the
antibiotic encapsulated in liposomes of all three compositions
was bactericidal in the spleen. PEG-DSPE-containing liposomes may have been less effective than the other liposomes in
the liver because of increased levels of circulation in blood and
uptake in other tissues (3, 46). While PI-containing liposomes
were effective in the liver and spleen, they were the least
effective liposome composition in terms of the CFU reduction
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in the lungs. The reasons for this observation are not obvious
at present. Previous studies with Klebsiella pneumoniae-infected rats have indicated that the percentage of hydrogenated
PI-containing liposomes that localize in the infected lungs is
much lower than that of PEG-DSPE-containing liposomes (7,
8). However, the degree of localization of the former liposomes in infected lungs was significantly higher than that of
PG-containing liposomes (8). Thus, it is difficult to correlate
localization in the lung with enhanced efficacy, particularly
since the two animal models are different. Furthermore, our
previous studies have indicated that the enhanced localization
of streptomycin in multilamellar liposomes in the lung compared with that of unilamellar liposomes does not result in
enhanced efficacy against MAC (17).
Our previous studies have shown that liposome-encapsulated streptomycin is more effective than the free antibiotic
against MAC even in cultured murine peritoneal (5) or human
peripheral blood monocyte (36) macrophages, suggesting that
liposomes can mediate the intracellular transport of streptomycin and its localization at high concentrations in the same
compartments as MAC. A similar mechanism is likely to operate in vivo. In addition, liposomes facilitate the localization
of the antibiotic in tissue macrophages since they are avidly
phagocytosed by these cells (14, 34, 40–42).
Liposomes containing solid-phase lipids, such as DSPC, and
cholesterol are known to be more stable in plasma than those
composed of fluid-phase lipids or those not containing cholesterol (42). It is possible that the improved liposome stability in
plasma may prevent the release of encapsulated antibiotics
once the liposomes are endocytosed by macrophages. For example, the intracellular release of ampicillin encapsulated in
solid liposomes composed of PG-DSPC-chol (molar ratio,
1:10:10) was delayed compared with that of ampicillin encapsulated in fluid liposomes (phosphatidylserine-PC-chol [molar
ratio, 1:4:5]), as evidenced by the killing of intracellular Listeria
monocytogenes (6). Our results with DSPC-cholesterol-containing liposomes demonstrate, however, that encapsulated
streptomycin is available in MAC-infected tissues and cells and
can kill or inhibit the growth of MAC. Thus, sterically stabilized liposomes with prolonged circulation times, such as those
composed of PEG-DSPE–DSPC–chol, can be used effectively
to deliver antibiotics to tissues and infected macrophages.
These liposomes did not exhibit a particular advantage over
conventional liposomes in reducing the CFU in the tissues
examined in the present study. However, since sterically stabilized liposomes have been shown to extravasate into deep
tissues and localize in tissue macrophages, it is likely that they
may be able to transport antibiotics to MAC-infected macrophages in the intestines, lymph nodes, and other tissues. Liposomes with prolonged circulation times may also be effective in
reducing the level of bacteremia. These aspects will be examined in future studies.
Our observations also demonstrate that twice-weekly administration of streptomycin encapsulated in PG-PC-chol or PEGDSPE–DSPE–chol liposomes can reduce the level of MAC
infection in the lungs by several orders of magnitude. This
result demonstrates that liposome-encapsulated aminoglycosides can reduce the MAC CFU counts in the lungs at doses
much lower than the free intramuscular doses required for
achieving the same effect (17, 21). The ability to reduce levels
of mycobacterial infection in the lungs with liposomes may also
provide the opportunity to treat Mycobacterium tuberculosis
infections by the same technique.
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